These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29935857)

  • 1. Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Secord AA; Previs RA; Nixon AB
    Gynecol Oncol; 2018 Jul; 150(1):1-2. PubMed ID: 29935857
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Konstantinopoulos PA; Brady WE; Farley J; Armstrong A; Uyar DS; Gershenson DM
    Gynecol Oncol; 2018 Jul; 150(1):9-13. PubMed ID: 29739622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
    Bergerot P; Lamb P; Wang E; Pal SK
    Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
    Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
    Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib Unlocks Efficient
    Chaudagar KK; Landon-Brace N; Solanki A; Hieromnimon HM; Hegermiller E; Li W; Shao Y; Joseph J; Wilkins DJ; Bynoe KM; Li XL; Clohessy JG; Ullas S; Karp JM; Patnaik A
    Mol Cancer Ther; 2021 Feb; 20(2):438-449. PubMed ID: 33277441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib in prostate cancer: the beginning of a precision paradigm?
    Goodin S; DiPaola RS
    J Clin Oncol; 2013 Feb; 31(4):401-3. PubMed ID: 23248244
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib.
    Mennitto A; Verzoni E; Peverelli G; Alessi A; Procopio G
    Clin Genitourin Cancer; 2018 Jun; 16(3):e521-e523. PubMed ID: 29656939
    [No Abstract]   [Full Text] [Related]  

  • 13. New Indication for Cabozantinib.
    Aschenbrenner DS
    Am J Nurs; 2022 Jan; 122(1):20-21. PubMed ID: 34941589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: cabozantinib reduces pain and narcotic use in men with CRPC.
    Clyne M
    Nat Rev Urol; 2014 Apr; 11(4):188. PubMed ID: 24619377
    [No Abstract]   [Full Text] [Related]  

  • 17. Cabozantinib in genitourinary malignancies.
    Zhang T; Park SE; Hong C; George DJ
    Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
    Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
    Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
    Lendvai N; Yee AJ; Tsakos I; Alexander A; Devlin SM; Hassoun H; Korde N; Lesokhin AM; Landau H; Mailankody S; Koehne G; Chung DJ; Landgren O; Raje NS; Giralt S
    Blood; 2016 May; 127(19):2355-6. PubMed ID: 27020089
    [No Abstract]   [Full Text] [Related]  

  • 20. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
    Zhang L; Scorsone K; Woodfield SE; Zage PE
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.